Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Pharmacodynamics
- Sponsors XERIS Pharmaceuticals
- 20 Oct 2018 Planned End Date changed from 31 Jan 2019 to 30 Sep 2019.
- 20 Oct 2018 Planned primary completion date changed from 31 Jul 2018 to 31 Mar 2019.
- 31 Aug 2018 Biomarkers information updated